Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbisko Cayman Limited ( (HK:2256) ) has shared an announcement.
Abbisko Cayman Limited has granted 290,000 share options to three employees under its Post-IPO Share Option Scheme, with an exercise price of HK$13.14, vesting in four equal tranches on each anniversary from April 8, 2027 to April 8, 2030, subject to both group-level and individual performance targets. The company has also set a maximum 10-year exercise period and a clawback mechanism under which unvested options lapse automatically if an employee is summarily terminated for misconduct or similar serious grounds, underlining a tighter alignment between long-term employee incentives, corporate performance and governance standards.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a Hong Kong-listed company incorporated in the Cayman Islands with limited liability and trades under stock code 2256. The group operates in the biopharmaceutical sector, focusing on innovative drug research and development, and uses equity-based incentives to attract and retain professional talent critical to its growth strategy.
Average Trading Volume: 1,774,562
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.02B
Learn more about 2256 stock on TipRanks’ Stock Analysis page.